Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.

ABSTRACT:

Purpose

Intravitreal anti-vascular endothelial growth factor (VEGF) agents are effective in the treatment of central involving diabetic macular oedema (DMO). Vitreoretinal interface abnormalities (VRIA) are common in patients with DMO, and the effect of these on the response to anti-VEGF treatment is unclear. Furthermore the effect of anti-VEGF agents on the VRIA itself is uncertain.

Method

Prospective study of consecutive patients treated with ranibizumab (RZB) for DMO as part of routine clinical care in one eye unit over a 1-year period. Visual acuity (Va), central retinal thickness (CRT) and injection frequency data was recorded on an electronic database. Treatment was initiated with four monthly RZB injections and then a monthly PRN regime. All patients underwent high-de

SUBMITTER: Wong Y 

PROVIDER: S-EPMC5364245 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature